096 – Q2-2021 Biotech Earnings – Commercial-Stage Biotech Suffers!

As Q2-2021 earnings season comes to a close, I decided to do a recap on multiple biotech companies I’m interested in, providing updates from each one’s Q2 report. Commercial-stage biotech continues to be a risky place to invest, but there are some bright spots we can look towards that I’ll share in this episode.

Here is the breakdown:

$BIIB – 00:45 $BCEL – 8:36 $AUPH – 15:57 $TGTX – 18:50 $KPTI – 24:00 $CRIS – 26:52 $BTAI – 30:20 $RGNX – 32:50 $MDGL – 36:39 $VKTX – 39:30 $SAVA – 41:18 $FDMT – 46:00 $SELB – 47:40

Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech

Follow me on twitter @matthewlepoire

Send me an email matthewlepoire@gmail.com

http://www.breakingbiotech.com #breakingbiotech

Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

 

Leave a Reply

%d bloggers like this: